Live
- Film actor Mohan Babu knocks High Court doors. Requests for anticipatory bail
- Allu Arjun Seeks Lunch Motion; Court Hearing Scheduled for 2 PM Today
- Vijayawada hosts Swarnandhra Vision-2047 Program to foster development in AP
- World Bank okays loan for new project to boost earnings of UP farmers
- Zomato gets GST tax demand notice of Rs 803 crore
- Atul Subhash suicide: No arrests made yet, says Bengaluru Police Commissioner
- Indian agrochemicals sector to see 7-9 pc growth next fiscal: Report
- SC refers to CJI Cong leader’s petition for verification of EVMs used in Haryana polls
- To become the youngest world champion is truly a great feat: Gill congratulates Gukesh
- Case Filed Against Allu Arjun Under Four Sections
RLS gets DCGI nod for Corona drug Favipiravir
RLS gets DCGI nod for Corona drug Favipiravir
City-based Raghava Life Sciences Limited (RLS) on Monday said it received Drug Controller General of India (DCGI) approval to manufacture and market bulk drug (API) for Favipiravir which is being widely used for the treatment of Covid-19
Hyderabad: City-based Raghava Life Sciences Limited (RLS) on Monday said it received Drug Controller General of India (DCGI) approval to manufacture and market bulk drug (API) for Favipiravir which is being widely used for the treatment of Covid-19.
RLS Managing Director P Lohit Reddy said that pharma companies such as Lupin, Hetero, Cipla and Sun Pharma recently launched oral pills of favipiravir under their own brands at competitive prices.
"Favipiravir is being widely considered successful in treating Covid patients. The medicine is currently being prescribed to Covid-19 patients with mild to moderate symptoms.
A data from clinical trials involving 150 subjects showed that about 70 per cent of the patients being treated with the drug achieved clinical cure by the fourth day of the study, compared with about 45 per cent in the standard care group," Reddy said.
Advanced stage trials of favipiravir are currently underway in several countries including India. RLS, which also specializes in contract research projects, received approval to supply the active pharmaceutical ingredient (API) of the drug to formulation companies.
